Laboratory for Surfactant Research, Department of Molecular Medicine and Surgery, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden.
Department of Physiology, Jessenius Faculty of Medicine, Comenius University, Mala Hora 4C, 036 01, Martin, Slovakia.
Sci Rep. 2021 Jan 8;11(1):22. doi: 10.1038/s41598-020-79679-z.
During postnatal adaptation pulmonary surfactant may be inactivated by lipopolysaccharide (LPS). We evaluated the effect of surfactant therapy in combination with antibiotic polymyxin B (PxB) in double-hit model of neonatal lung injury. Surfactant (poractant alfa, Curosurf) was exposed to smooth (S) LPS without/with PxB and tested in captive bubble surfactometer. Preterm rabbits received intratracheally saline (control) or S-LPS and were ventilated with 100% oxygen. After 30 min, LPS-treated animals received no treatment, or surfactant (200 mg/kg) without/with 3% PxB; controls received the same dose of surfactant. Animals were ventilated for further 2 h. In vitro, addition of 5% S-LPS to surfactant increased minimum surface tension (γmin) and addition of 1-3% PxB to surfactant/S-LPS mixture restored γmin to low values. Animals only given S-LPS had lower lung compliance and lung gas volume (LGV) compared to surfactant groups. Treatment with surfactant/PxB, but not with surfactant only, restored LGV. Addition of PxB to the surfactant increased the alveolar expansion. S-LPS interferes with surface activity of the pulmonary surfactant and PxB improves the resistance of surfactant to LPS-induced inactivation. In our neonatal model of respiratory distress syndrome surfactant gives positive response even in simultaneous exposure to S-LPS, when enriched with PxB.
在产后适应过程中,肺表面活性剂可能会被脂多糖(LPS)灭活。我们评估了表面活性剂治疗联合抗生素多粘菌素 B(PxB)在新生儿肺损伤双重打击模型中的作用。表面活性剂(猪肺磷脂 alfa,Curosurf)暴露于光滑 LPS 下,无/有 PxB,并在封闭气泡表面张力仪中进行测试。早产兔经气管内给予生理盐水(对照)或 S-LPS,并接受 100%氧气通气。30 分钟后,LPS 处理的动物接受无治疗、表面活性剂(200mg/kg)无/有 3% PxB;对照组给予相同剂量的表面活性剂。动物进一步通气 2 小时。在体外,向表面活性剂中添加 5% S-LPS 会增加最小表面张力(γmin),向表面活性剂/S-LPS 混合物中添加 1-3% PxB 会将 γmin 恢复到低值。仅给予 S-LPS 的动物的肺顺应性和肺气体容积(LGV)低于表面活性剂组。用表面活性剂/PxB 治疗,但不用表面活性剂治疗,可恢复 LGV。向表面活性剂中添加 PxB 会增加肺泡扩张。S-LPS 会干扰肺表面活性剂的表面活性,而 PxB 可提高表面活性剂对 LPS 诱导失活的抵抗力。在我们的新生儿呼吸窘迫综合征模型中,即使同时暴露于 S-LPS 时,表面活性剂在与 PxB 联合使用时也会产生积极反应。